There is a version of this conversation that treats HCP AI adoption as something to watch. That version is outdated.

As of early 2026, 54% of healthcare professionals are already using generative AI to access scientific information, per IQVIA's EMEA report. The AMA adds: 66% of US physicians now use AI in practice, with 37% doing so daily. These are not projections. They describe how a majority of the physicians your reps are visiting right now are processing medical information.

The question is no longer "are HCPs using AI?" It is "does our engagement strategy reflect the HCP who already is?"

The Behavior Data Underneath the Adoption Numbers

Adoption figures are one thing. What HCPs are doing with AI is where the real signal is.

Among HCP AI users, 94% say it makes medical information easier to find. But the more important number is this: 72% say AI helps them make better treatment decisions. That is not a convenience statement. That is a clinical confidence statement. When nearly three in four AI-using HCPs say it improves their decision quality, the channel has moved well past information retrieval into something that shapes judgment.

For medical affairs, this changes what scientific exchange needs to account for. For commercial teams, it changes what a complete HCP engagement strategy actually looks like.

The Segmentation Gap This Exposes

Most pharma segmentation models were built around HCP behavior that predates this shift. They account for prescription volume, specialty, and channel preference. Very few account for AI fluency as a variable in how an HCP evaluates product information.

That gap matters. An HCP who consults AI daily before a rep visit is not the same engagement target as one who does not. Their information environment is different, and what moves them is different. Treating them identically is a structural inefficiency in your targeting.

This is where the real strategic work begins: not reacting to AI adoption as a trend, but rebuilding HCP segmentation around the reality that a meaningful portion of your audience now has an AI-assisted clinical workflow.

PharmaServ gives life science commercial and medical affairs teams the targeting precision and HCP intelligence to do exactly that. The platform is built for teams that want to engage HCPs based on how they actually behave now, not how they behaved three years ago.

'

The data is settled. The planning gap is what still needs closing.

Sources: IQVIA EMEA, March 2026; American Medical Association, 2026